Rheumatic heart disease (RHD) continues to be responsible for major cardiovascular morbidity and mortality in the developing world. It constitutes a double tragedy because it disproportionately affects economically disadvantaged people and young people, thereby robbing them of the most productive years of life.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Valve Disease
February 4, 2021
December 10, 2020
An ad hoc interim analysis pursuant to previous publications raising concerns on Paclitaxel DCS in chronic critical and not-critical lower limb ischaemia. The short manuscript requires careful reading to form an individual opinion beyond the relatively simple arithmetics: slightly more deaths in the intervention group.
December 4, 2020
A brief and readable editorial on the United Kingdom prespective on the global impact of the pandemic to the delivery of cardiovascular care, attempting a semi-quantitative economic appraisal of the problem.
November 28, 2020
A large RCT with results somewhat supportive of considering a NOAC in the place of warfarin for post operative surgical patients. The study will be weighed against healthcare economical aspects.
June 30, 2020
Researchers from the UK reported a novel polymeric heart valve, PoliValve, which is made entirely from styrenic block copolymers.
February 26, 2020
Five year results of the PARTNER II trial demonstrated no difference in the risk of stroke or death comparing TAVR to surgical aortic valve replacement among intermediate surgical risk patients.
February 24, 2020
In 2014, Edwards Lifescience launched an ambitious philanthropic initiative called Every Heartbeat Matters (EHM) with the goal of impacting the global burden of heart valve disease through the education, screening and treatment of 1 million underserved people by 2020.
January 8, 2020
A medium size RCT with encouraging surgical outcomes in the era of TAVI expansion.....
November 22, 2019
Puzzling subgroup from the GALILEO trial, which appears in the same issue of the periodical as an article that discredits the use of rivaroxaban as thromboprevention strategy :
November 7, 2019
Data from the PARTNER trials were assessed regarding post-procedural prosthetic valve endocarditis (PVE) after transcatheter aortic valve replacement and surgical aortic valve replacement. The timing and rates of PVE were similar between the groups, and they had a similar high mortality.